A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment
- PDF / 1,134,631 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 97 Downloads / 197 Views
ORIGINAL ARTICLE
A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment Zegeng Chen 1 & Xiaojie Fang 1 & He Huang 1 & Zhao Wang 1 & Huangming Hong 2 & Meiting Chen 1 & Quanguang Ren 1 & Yuyi Yao 1 & Limei Zhang 1 & Ying Tian 1 & Suxia Lin 1 & Tongyu Lin 1,3 Received: 7 May 2020 / Accepted: 17 September 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract In the era of asparaginase-based therapy for extranodal natural killer/T cell lymphoma (ENKTL), the clinical outcomes of ENKTL have notably improved. However, as a rare subtype of ENKTL, the therapeutic effect and prognostic factors of nonnasal type ENKTL remain unclear. Thus, we performed this study to analyze the clinical characteristics and to establish a prognostic model specifically for the non-nasal disease. We performed a retrospective study of consecutive patients newly diagnosed with non-nasal type ENKTL and mainly received asparaginase-based therapy at Sun Yat-sen University Cancer Center (SYSUCC) between January 2011 and December 2019, to analyze the prognostic factors and to propose a prognostic model. We validated the prognostic model in an independent cohort. In total, 98 non-nasal type ENKTL patients were included in the training cohort. Multivariate analyses showed that prognostic factors for OS were elevated LDH levels, involvement of bone marrow and serum total protein (TP) < 60 g/L. We developed a new prognostic model named the non-nasal type ENKTL prognostic index (NPI) by grouping the prognostic factors: group 1, no risk factors; group 2, one risk factor; and group 3, two or three risk factors, which were associated with 3-year OS rates of 84.1% (95% CI, 70.9–97.2), 46.8% (27.7–65.8), and 14.9% (0– 32.9), respectively (P < 0.001). These results were validated and confirmed in an independent cohort. The new model is efficient in distinguishing non-nasal-type ENKTL patients with various outcomes in the contemporary era of asparaginase-based therapy. Keywords Non-nasal type . Natural killer/T cell lymphoma . Prognostic model . Overall survival
Introduction As a unique subtype of non-Hodgkin’s lymphoma, extranodal natural killer/T cell lymphoma (ENKTL) is defined by characteristics such as vascular damage, obvious necrosis, and cytotoxic phenotype; it has a high prevalence particularly in Zegeng Chen and Xiaojie Fang contributed equally to this work. * Tongyu Lin [email protected] 1
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
2
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
3
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, 651 Dongfeng Road East, Guangzhou 510060, Guangdong, China
east Asia and Latin America and is related to Epstein–Barr virus [1–3]. In the era of asparaginase-based t
Data Loading...
